IBM Granted Patent for Antigen-Binding Proteins Targeting SARS-CoV-2 Variants
Summary
USPTO granted IBM (International Business Machines Corporation) Patent US12600764B2 for antigen-binding proteins capable of binding to SARS-CoV-2 coronavirus variants. The patent covers compositions comprising heavy polypeptide chain variable regions with specific amino acid substitutions (R50, I54, L55 positions) that enhance binding to CoV variants. The patent includes 14 claims and was filed on August 27, 2021.
What changed
USPTO granted IBM Patent US12600764B2 for antigen-binding proteins targeting SARS-CoV-2 coronavirus variants. The patent claims compositions comprising heavy polypeptide chain variable regions with amino acid sequences derived from SEQ ID NO: 7, incorporating substitutions such as R50D/E/W/F/Y/L/V/I/Pho, I54D/E/W/F/Y/Pho, and L55D/E/W/F/Y/Pho. The patent names Binquan Luan, Leili Zhang, and Tien Huynh as inventors and contains 14 allowed claims.
For pharmaceutical and biotechnology entities developing coronavirus therapeutics or diagnostics, this patent establishes IBM's intellectual property rights over specific antigen-binding protein sequences with enhanced variant binding properties. Companies should consider potential licensing needs or design-around strategies for any therapeutic programs involving similar antibody or protein scaffold technologies targeting SARS-CoV-2 variants.
What to do next
- Monitor patent landscape for related therapeutic applications
- Review licensing opportunities for coronavirus variant binding technologies
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antigen-binding proteins targeting coronavirus (COV) variants
Grant US12600764B2 Kind: B2 Apr 14, 2026
Assignee
INTERNATIONAL BUSINESS MACHINES CORPORATION
Inventors
Binquan Luan, Leili Zhang, Tien Huynh
Abstract
Techniques regarding antigen-binding proteins that can bind to CoV (e.g., SARS-CoV-2) variants are provided. For example, one or more embodiments described herein can comprise an antigen-binding protein that can comprise a heavy polypeptide chain variable region with an amino acid sequence that is a variant of SEQ ID NO: 7. The amino acid sequence can comprise at least one amino acid substitution selected from the group consisting of: R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, R50Pho, I54D, I54E, I54W, I54F, I54Y, I54Pho, L55D, L55E, L55W, L55F, L55Y, and L55Pho.
CPC Classifications
C07K 14/005 C07K 16/1003 C07K 2317/55 C07K 2317/56 C07K 2317/565
Filing Date
2021-08-27
Application No.
17459486
Claims
14
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.